Latest Conference Coverage

Collaboration and Innovation in Alzheimer Disease Clinical Trial Research: Howard Fillit, MD

The cofounder and chief science officer of the Alzheimer's Drug Discovery Foundation highlighted the critical role of collaboration and innovative diagnostics for advancing Alzheimer disease care. [WATCH TIME: 4 minutes]

Conway CuTS Scale Predicts Impairment Better Than Traditional Scales After Cubital Tunnel Syndrome Surgery

The study, presented at the 2024 AANEM) Annual Meeting, evaluated 52 patients who underwent surgery for carpal tunnel syndrome and explored the comparative effectiveness of the Conway and Zeidman scales in predicting patient outcomes.

Redesigning Clinical Trials in Alzheimer Disease to Promote Diversity and Accessibility

Jessica Langbaum, PhD, the senior director of research strategy at Banner Alzheimer’s Institute, discussed the challenges and opportunities in improving diversity in Alzheimer disease clinical trials.

Study Details of Phase 2 KYSA-6 Trial of CAR-T Therapy in Myasthenia Gravis Presented

The multicenter, 24-week study will feature 20 patients with MG, testing changes on MG-ADL as well as several other secondary outcomes, including patient-reported assessments.

Subcutaneous Efgartigimod Demonstrates Efficacy, Safety in Seronegative Myasthenia Gravis

Overall, subcutaneous efgartigimod was safe and effective in patients with seropositive MG, demonstrated by consistent improvements in Myasthenia Gravis-Activites of Daily Living.

Exploring Blood-Based Biomarkers and Treatment Eligibility in Alzheimer Disease: Gil Rabinovici, MD

The professor of neurology and radiology at University of California, San Francisco, discussed the potential of blood-based biomarkers in Alzheimer treatment eligibility, highlighting current limitations and the importance of safety monitoring. [WATCH TIME: 7 minutes]

Highlights on Exploring Advances in Headache Medicine from AHS Scottsdale 2024: MaryAnn Mays, MD

Phase 2a Trial to Test Effects of Antiseizure Medication Lamotrigine in Dementia With Lewy Bodies

The trial, a 20-week study assessing lamotrigine in DLB, will use change in Clinical Dementia Rating-Sum of Boxes as the primary efficacy end point, with several other notable secondary outcomes.

Medication Compliance High With Self-Administered Ziluocoplan in Myasthenia Gravis

For more than a 2-year treatment period, 95% of patients reported taking at least 95% of their daily medications with zilucoplan.

NeuroVoices: Charbel Moussa, PhD, MBBS, on Therapeutic Potential of Nilotinib in Dementia With Lewy Bodies

The associate professor of neurology at Georgetown University provided clinical insight on the origins of nilotinib and its medicinal promise in treating patients with Dementia with Lewy bodies, a neurodegenerative disorder.

Challenges in Identifying Optimal Candidates for Muscular Dystrophy Gene Therapies: Melissa Spencer, PhD

The professor in residence at UCLA Health discussed the critical considerations when deciding appropriate patients for gene therapies, specifically AAV vectors, in treating muscular dystrophies. [WATCH TIME: 4 minutes]

Need for Better, More Specific Delivery Methods for Gene Therapies in Muscular Dystrophy: Melissa Spencer, PhD

The professor in residence at UCLA Health provided clinical insight on the limitations of certain gene therapy vehicles for muscular dystrophies, and the need for better vectors that are more myotropic. [WATCH TIME: 3 minutes]

Educational Benefits of Flipped Classrooms in Teaching Settings: Lawrence Robinson, MD

The senior scientist at Sunnybrook Research Institute in Toronto, Ontario, provided clinical insight on the advantages of a flipped classroom, and why neurology educators should consider this approach. [WATCH TIME: 2 minutes]

Guidance on Safe Use of Donanemab for Alzheimer Disease in Clinical Settings: Gil Rabinovici, MD

The professor of neurology and radiology at University of California, San Francisco talked about how the new appropriate use recommendations of donanemab aims to safely integrate this anti-amyloid antibody into the clinical practice. [WATCH TIME: 7 minutes]

Clinical Validation and Real-World Impact of PrecivityAD2 Test for Alzheimer Diagnosis: Joel B. Braunstein, MD

The CEO at C2N Diagnostics talked about the clinical utility of the company’s PrecivityAD2 test, which uses the p-tau 217 biomarker and amyloid-β measurements, to increase diagnostic confidence and influence treatment decisions in Alzheimer disease. [WATCH TIME: 7 minutes]

Improving Alzheimer Diagnosis With Innovative Blood-Based Biomarker Tests and BD-Tau: Mike Miller, PhD

The chief operating officer at Quanterix Corporation talked about pioneering ultra-sensitive blood biomarkers for Alzheimer clinical diagnosis, aiming to enhance detection of brain-derived tau and amyloid status with innovative assays. [WATCH TIME: 4 minutes]

Social Determinants of Health and the Reasons Behind Missed Diagnosis and Misdiagnosis of Myasthenia Gravis

Judith Thompson, PharmD, MPH, CPHQ, rare disease population health strategy lead at UCB, discussed the association between social determinants of health and delayed diagnosis/misdiagnosis in myasthenia gravis.

Early Clinical Use of Anti-Amyloid Therapy for Alzheimer Disease in Japan: Takeshi Iwatsubo, MD, PhD

The professor of neuropathology at the University of Tokyo School of Medicine talked about the latest data on lecanemab use in clinical practice for Alzheimer disease in Japan presented at CTAD 2024. [WATCH TIME: 4 minutes]

Assessing Phase 2 Data on Bepranemab’s Effect on Tau Accumulation and Cognitive Function: Matthew Barton, PhD

The head of global clinical development for immunology/bone at UCB talked about findings presented at CTAD 2024 from the phase 2 trial assessing bepranemab in Alzheimer disease. [WATCH TIME: 3 minutes]

Current Use and Future Potential of Blood Biomarkers for Advancing Alzheimer Diagnosis: Rebecca M. Edelmayer, PhD

The vice president of scientific engagement at the Alzheimer's Association talked about the emergence of blood biomarker tests as valuable diagnostic tools for Alzheimer disease in the clinical setting. [WATCH TIME: 5 minutes]

Phase 2 cAPPricorn Study to Assess RNA Therapeutic Mivelsiran in Cerebral Amyloid Angiopathy

The cAPPricorn-1 Phase 2 trial will assess mivelsiran’s efficacy in CAA, focusing on reducing the annualized rate of new cerebral microbleeds over 24 months.

Predicting Response to Cannabinoid Treatment for Agitation in Alzheimer Disease: Krista L. Lanctôt, PhD

The professor of psychiatry and pharmacology at the University of Toronto talked about results from a post hoc analysis presented at CTAD 2024 that explored synthetic cannabinoid nabilone for agitation in Alzheimer disease. [WATCH TIME: 4 minutes]

The Promise of Personalized Neurostimulation in Slowing Alzheimer Progression: Giacomo Koch, MD, PhD; Ken Mariash; Emiliano Santarnecchi, PhD

A trio of experts from Sinaptica Therapeutics talked about recent findings presented at CTAD 2024 from a study assessing personalized transcranial magnetic stimulation in patients with Alzheimer disease. [WATCH TIME: 5 minutes]

NeuroVoices: Richard Nowak, MD, MS, on the MINT Trial of Inebilizumab in Myasthenia Gravis

The director of the myasthenia gravis clinic at Yale University discussed the therapeutic potential of inebilizumab, an FDA-approved treatment for NMOSD, in myasthenia gravis, based on data from the phase 3 MINT study.

Addressing Treatment Gaps in Adolescents With Myasthenia Gravis: Jonathan Strober, MD

The director of the Muscular Dystrophy Clinic at UCSF Benioff Children’s Hospital provided insight on promising data from the phase 2/3 VIBRANCE-MG study assessing investigational nipocalimab in adolesents with myasthenia gravis. [WATCH TIME: 3 minutes]

Pepinemab Produces Positive Effects on Plasma Biomarkers and Cognitive Measures in Phase 1b/2 SIGNAL-AD Trial

SIGMAR1 Activating Agent Blarcamesine Meets Pre-Specified Efficacy in Phase 2/3 Trial of Alzheimer Disease

Over a 48-week treatment period, once daily blarcamesine slowed clinical decline in patients with early-stage Alzheimer disease, with even more pronounced effects in pre-specified common SIGMAR1 wild type group.

Latest Brainshuttle AD Study Interim Data Support Continued Trontinemab Development for Alzheimer Disease

At week 25 of treatment with trontinemab, patients demonstrated decreases in CSF total tau, CSF p-tau181, and CSF neurogranin.

Enhancing Diversity and Accessibility in Clinical Trials for Alzheimer Disease: Jessica Langbaum, PhD

The senior director of research strategy at Banner Alzheimer’s Institute talked about improving clinical trial diversity through removal of logistical barriers, creating inclusive outreach strategies, and designing trials that address the unique needs of underrepresented populations. [WATCH TIME: 5 minutes]

Marking a New Era in Patient Care With Advancements in Disease-Modifying Alzheimer Treatments: Alireza Atri, MD, PhD

The director of the Banner Sun Health Research Institute talked about how the newly approved Alzheimer treatments have shown promise in slowing clinical decline, signaling a foundational shift toward disease-modifying therapies that target core biological processes. [WATCH TIME: 5 minutes]